Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as the general partner, has made an investment in Kyoto University Research Institute for Drug Discovery Inc. (Head office: Sakyo-ku, Kyoto; Representative Director: Kunihiro Musashi), a venture company that utilizes research results from Kyoto University.

0Execution of Investment in Kyoto Institute for Drug Discovery
Kyoto Institute for Drug Discovery is a company that develops novel therapeutic agents for intractable ocular diseases such as central retinal artery occlusion (CRAO), retinitis pigmentosa, and glaucoma using novel small molecule compounds ("KUS agents") jointly developed by the Graduate School of Life Sciences, Kyoto University (Professor Akira Kakizuka), Graduate School of Medicine, Kyoto University (Specially Appointed Professor Nagahisa Yoshimura, Former Professor of Ophthalmology), and the Integrated Clinical Research Center, Kyoto University Hospital (Associate Professor Hanako Ikeda). and retinitis pigmentosa, as well as other rare diseases such as glaucoma and other intractable ocular diseases.

Since the third-party allocation of new shares (totaling 380 million yen) in June 2016, the company has been working to maximize the value of this program by supporting physician-led clinical trials at Kyoto University Hospital and continuing research and development, including the expansion of indications for KUS agents.

Kyoto iCAP continues to expect that the KUS agent will meet the unmet needs of patients with intractable diseases, particularly in the field of ophthalmology, and has underwritten a third-party allocation of new shares totaling 143 million yen with Mitsubishi UFJ Capital Limited (Head Office: Chuo-ku, Tokyo; President: Muneki Handa), of which 101 million yen has been invested. The investment amounted to 101 million yen.

Outline of Kyoto Institute for Drug Discovery Research, Inc.

Establishment	May 2015
Business	Development of novel therapeutic agents for intractable ocular diseases using KUS agents
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Kunihiro Musashi